Wallwiener Markus, Heindl Felix, Brucker Sara Y, Taran Florin-Andrei, Hartkopf Andreas, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Ettl Johannes, Lux Michael P, Rauh Claudia, Blum Simon, Nabieva Naiba, Brodkorb Tobias F, Faschingbauer Cornelia, Langemann Hanna, Schulmeyer Carla, Volz Bernhard, Rübner Matthias, Lüftner Diana, Müller Volkmar, Belleville Erik, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Ganslandt Thomas, Beckmann Matthias W, Schneeweiss Andreas, Fasching Peter A, Gass Paul
Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University of Erlangen-Nuremberg, Germany.
Geburtshilfe Frauenheilkd. 2017 Aug;77(8):870-878. doi: 10.1055/s-0043-116223. Epub 2017 Aug 24.
Patient-reported outcomes (PROs) have been incorporated into clinical trials for many symptoms and medical conditions. A transition from paper-based capture of PROs to electronic PROs (ePROs) has recently started. This study reports on the feasibility of ePRO assessment in a prospective registry including molecular data for patients with advanced breast cancer.
As part of the PRAEGNANT network, patients were invited by clinical trial staff, physicians, and nurses to complete three standardized Internet-based questionnaires (EQ 5D 5 L, CES-D and IPAQ). Feasibility was assessed by the staff members who assigned the user accounts by the patients. The completeness of the questionnaires was also assessed.
Fifteen of 17 patients who were asked agreed to participate to complete the PRO questionnaires (EQ-5D-5L and CES-D). However, the IPAQ (physical activity) questionnaire was only validly completed by 9 patients. Feasibility was ranked better by the physicians and dedicated clinical trial staff than by the nursing staff.
Incorporating ePRO questionnaires into an advanced breast cancer registry is feasible, and no major hurdles were reported. Involving stakeholders from the start, the application is tailored to the capacities and abilities of both patients and clinical staff. The patients' compliance was better with some questionnaires, but others may present difficulties.
患者报告结局(PROs)已被纳入针对多种症状和医疗状况的临床试验中。最近已开始从基于纸质的PROs记录向电子PROs(ePROs)转变。本研究报告了在一个前瞻性登记处进行ePRO评估的可行性,该登记处包含晚期乳腺癌患者的分子数据。
作为PRAEGNANT网络的一部分,临床试验工作人员、医生和护士邀请患者完成三份标准化的基于互联网的问卷(EQ 5D 5L、CES-D和IPAQ)。由为患者分配用户账户的工作人员评估可行性。还对问卷的完整性进行了评估。
被邀请的17名患者中有15名同意参与完成PRO问卷(EQ-5D-5L和CES-D)。然而,只有9名患者有效完成了IPAQ(身体活动)问卷。医生和专业临床试验工作人员对可行性的评价高于护理人员。
将ePRO问卷纳入晚期乳腺癌登记处是可行的,且未报告重大障碍。从一开始就让利益相关者参与进来,该应用程序是根据患者和临床工作人员的能力量身定制的。患者对某些问卷的依从性较好,但其他问卷可能会带来困难。